The future of prescription drugs might be on the verge of changing. And a publicly traded company is behind it.
What’s happening:
- Wellgistics Health (NASDAQ: WGRX) has been making a flurry of moves recently to be on the leading edge of disrupting the paradigm of prescription drug delivery in the United States of America
By the numbers:
- Wellgistics Health has existing distribution agreements with 5,000 pharmacies in the United States of America
- Currently, Wellgistics Health is licensed in 35 different states
Why it matters:
- Wellgistics Health is one of the few publicly traded companies in North America focused on disrupting the traditional distribution model between pharmaceutical companies and patients
Going deeper:
- Wellgistics Health has built a artificial intelligence technology platform known as Wellgistics Hub which is capable of streamlining the process of patients directly receiving medication without the need for a pharmacy and is capable of rapidly verifying insurance and finding the lowest cost drugs available
- Disrupting the traditional pharmaceutical distribution network has also been a major theme in Silicon Valley, which has led to companies such as billionaire Mark Cuban’s Cost Plus Drugs being formed
The intrigue:
- Wellgistics Health also recently made waves when they struck a notable partnership with Protega Pharmaceuticals to distribute ROXYBOND, which is the first ever abuse deterrent, immediate release opioid medication to be approved by the United States Food and Drug Administration for treating pain
